Krsnaa Diagnostics Partners with Apulki Healthcare for Cancer and Cardiac Care

Key Takeaways from Krsnaa Diagnostics and Apulki Healthcare Partnership:

• Krsnaa Diagnostics has joined hands with Apulki Healthcare in an investment tie-up to form cancer and cardiac care hospitals in India.
• Through more than 30 years of being an exclusive diagnostics partner for Apulki healthcare, Krsnaa has consolidated its stance in the oncology and cardiac diagnostics market.
• The partnership will begin with the two 125 plus bed-capacity hospitals in Pune and Mumbai, then later expand into other metropolitan cities with more hospitals.
• Krsnaa and Apulki will offer round-the-clock comprehensive diagnostic services including MRI, PET CT, Cardiac CT, and advance pathology.
• A collaboration to deliver highest international standards in diagnostics for better prognosis with regard to early detection, treatment accuracy, and survival rates for cancer and cardiac patients.

As part of this, Krsnaa diagnostics has been chosen as the exclusive diagnostics partner for over 30 years for all the cancer and cardiac hospitals of Apulki. This partnership would initiate in the first phase two hospitals in the regions of Pune and Mumbai with over 125 beds in every hospital, and more hospitals are to be initiated in other metropolitan regions.

Krsnaa and Apulki will be offering services 24/7 with MRI, PET CT, Cardiac CT, and Advanced Pathology. This partnership will work toward seamless, world-class diagnostic solutions for patients being treated for both cancer and the cardiac clinical treatments at large, to enhance early detection and treatment accuracy and survival through timely and precise diagnoses.

Commenting on the development, Kinjal Babariya, Director of Apulki Healthcare, said, “This powerful collaboration ensures we are uniquely poised to capitalize on opportunities faster and more efficiently than any other player in the market. With this partnership we are eliminating the barriers of fragmented healthcare by integrating diagnostics and treatment under one roof.”

About Krsnaa Diagnostics Limited:

Krsnaa Diagnostics Limited is India's fastest-growing provider of diagnostic services in Radiology and Pathology having grown from two radiology centers in 2011 to well over 2,900 centers across 18 states and union territories. By focusing on giving quality diagnostics at accessible and affordable costs, Krsnaa has been able to offer clinical excellence through teleradiology that would support evidence-based treatment nationwide. They utilize state-of-the-art technology, including a cloud-based PACS workflow, to deliver fast, accurate reports from highly qualified experts all over the world. The company offers excellent service with quick turnaround of reports and convenient consultations while being a first CAP-accredited lab in India as a public-private partnership and possessing the largest NABH-accredited tele-radiology hub in Pune.

Key Takeaway from the Announcement 

• Torrent Pharma Chile is a wholly owned subsidiary of Torrent Pharmaceuticals, incorporated in Chile.
• The company has an initial authorised capital of 900 million Chilean pesos, aimed at supporting Torrent Pharma’s business in the region.
• The incorporation strengthens Torrent’s global footprint in the pharmaceutical industry.

As per a stock exchange filing, Torrent Pharmaceuticals Limited has incorporated a wholly owned subsidiary, Torrent Pharmaceuticals Chile SpA (“Torrent Pharma Chile”), on September 25, 2024, in Santiago, Chile. The new entity has an authorised and paid-up share capital of 900 million Chilean pesos and is fully owned by Torrent Pharmaceuticals, with the parent company holding 100% of the shares. 

While the primary purpose of Torrent Pharma Chile is to provide business support to Torrent Pharmaceuticals in Chile, this new entity has not begun operations, and its turnover is not meaningful since it is newly established. This incorporation does not involve related party transactions in the pre-formed context, but once it is formed, it is treated as a related party. - This action is consistent with Torrent Pharmaceuticals' strategic plan for growth around the world in the pharmaceutical industry.

About Torrent Pharmaceuticals Limited

Torrent Pharmaceuticals Ltd. is a major Indian pharmaceutical company involved in researching, developing, manufacturing, and marketing generic pharmaceutical formulations. Torrent Pharmaceuticals Ltd. is the only company of the Torrent Group, as the Torrent Group has other interests in the power and distribution of city gas. The company has a portfolio of pharmaceutical products covering a variety of dosage forms, including oral solids, oral liquids, topicals, suppositories, human insulin, and synthetic APIs; approximately 80% of its API production is used in-house.

Key Takeaways from EaseMyTrip Collaboration with PhonePe: 

• EaseMyTrip collaborates with PhonePe to launch the hotel booking segment. 
• With this partnership, the hotel deals and offers become exclusive, and are special for the PhonePe users, thereby adding immense value to their booking.
• Activities and Cabs will be inducted into the platform, while an attempt is made to provide the entire travel booking experience within the PhonePe application.
• EaseMyTrip Hotels will allow best price guarantees, flexibility in booking, and no charge cancellations so that the user benefits are maximised.
• The alliance would make travelling easier for millions of PhonePe users by integrating travel services under one roof.

PhonePe users would get exclusive access to an extremely wide range of hotel deals and offers, besides getting the option of hotel bookings. Other options like Activities and Cabs are also planned to be added soon, thereby completing the travel booking experience on PhonePe.

EaseMyTrip Hotels will now offer ease of design, competitive prices, and flexibility of booking with a free cancellation facility to PhonePe users.

This partnership is part of a larger strategy to enhance travel booking for millions of Indian PhonePe users. The EaseMyTrip-PhonePe partnership unites travel expertise and adds the depth of a comprehensive user base, as it plans to make travel planning easier for customers, where all the services can be availed through a single application.

Rikant Pittie, Co-Founder of EaseMyTrip said, “This partnership is a significant step in making travel more accessible and convenient for millions of users across India.” 

Commenting on the partnership, Sonika Chandra, Chief Business Office - Consumer Payments, PhonePe said, “We are excited to partner with EaseMyTrip to create a differentiated and seamless hotel booking experience for our users with the best deals on our platform.”

About EaseMyTrip:

EaseMyTrip is one of the largest online travel platforms in India for booking air tickets as was recently reported by Crisil in February 2021. The profits have surged at 47% from FY20 to FY24. The company had started with no external funding and hence was profitable since day one. EaseMyTrip's travel service range includes air tickets, hotel bookings, holiday packages, rail and bus tickets, and a number of value-added services. Users can book without convenience fees and more than 400 airlines along with over 2 million hotels across train, bus, and taxi services in major Indian cities. Founded in 2008, EaseMyTrip has offices spread across many Indian cities and also international offices in the Philippines, Singapore, Thailand, the UAE, UK, USA, and New Zealand.

About PhonePe Group:

PhonePe Group is one of the leading fintech companies in India that has, since August 2016, been running a mobile app for digital payments. The app became the country's top consumer payments app within eight years of history, with over 560 million registered users and over 40 million merchant partners. It processes over 280 million transactions daily, which amounts to over $1.5 trillion annually. From its foray into digital payments, PhonePe has ventured into financial services that include insurance and lending, as well as new consumer tech ventures such as hyperlocal e-commerce and India's first localised app store. Today, it aims to make every Indian have access to better money and services.

Key takeaways from the Biocoin and Tabuk Pharma Agreement

• Biocon Limited has signed a licensing and supply agreement with Tabuk Pharmaceuticals to commercialise its GLP-1 products for diabetes and chronic weight management in the Middle East.
• Biocon will develop and manufacture the products, while Tabuk Pharmaceuticals will handle marketing, registration, import, and promotion in select Middle Eastern countries.
• The agreement includes provisions to expand into other GLP-1 products and an option for tech transfer to enable localised manufacturing in the future.

GLP-1 products are aimed at treating diabetes and chronic weight management in select countries within the Middle East region. 

Biocon will handle the development and manufacturing of the products, while Tabuk Pharmaceuticals will be responsible for marketing authorisation, registration, import, and promotion. The agreement also includes potential expansion to other GLP products, with an option for tech transfer for localised manufacturing in the future.

About GLP-1 Products 

Glucagon-like peptide-1 (GLP-1) medications are used to regulate blood sugar levels and aid in weight loss by enhancing insulin production, reducing glucagon secretion, and slowing gastric emptying. These physiological hormones improve glycaemic control and have been vital in managing diabetes.

This collaboration marks a significant step in improving access to affordable therapies for chronic conditions in the Middle East.

Commenting on the agreement, Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, said, “I am pleased to expand our partnership with Tabuk Pharmaceuticals, which paves the way for our vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other countries in the region. The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers. This is another important milestone for Biocon, reflecting our commitment to providing patients around the globe with affordable medications, by establishing a strong portfolio of products, either directly or through strategic partnerships.” 

Ismail Shehadah, Chief Executive Officer of Tabuk Pharmaceuticals, said, “We are excited to announce our partnership with Biocon that will enable us to deliver unique health solutions aimed at enhancing the well-being of people in Saudi Arabia and other countries we operate in. We are confident that this partnership supports our efforts to manufacture and localize a range of GLP-1 products in the region and strengthen our market leading position in the area of diabetes medications, in line with our strategy. This also stands as a commitment from our side to support the 2030 vision of Saudi Arabia through localizing specialty pharmaceutical products in the Kingdom.” 

About Biocon Limited 

Biocon Limited, listed on the stock exchange in 2004, is a global biopharmaceutical company focused on innovation. The company is dedicated to making advanced therapies for chronic conditions like diabetes, cancer, and autoimmune diseases more accessible and affordable. Biocon has introduced cutting-edge biologics, biosimilars, and small-molecule APIs in India and globally, including generic drugs in the U.S. and Europe. It is also working on developing new treatments in the field of immunotherapy. 

About Tabuk Pharmaceuticals 

Tabuk Pharmaceuticals, a prominent pharmaceutical company in Saudi Arabia, operates throughout the Middle East and North Africa (MENA) region. The company develops, manufactures, and distributes branded generic medicines and partners with international pharmaceutical companies to produce high-quality medicines at its facilities in Saudi Arabia. With over 2,400 employees, Tabuk Pharmaceuticals serves patients in 17 MENA countries and has plans to expand its presence further. Its manufacturing plants are located in Tabuk, Dammam, Sudan, and Algeria.